Free tool
Rare disease stocks
We cover 13 companies grouped under the Rare disease theme. The median market value in the group is $15.52B. Across the group, the median move over the past trading day is −0.45%. Price change over the past year runs from −3.7% to +204.6% across the middle 80 percent of the group, with a median of +60.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
13 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $138.63B | Large cap | +40.66% | Nov 2, 2026 |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% | Oct 22, 2026 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $32.12B | Large cap | −47.38% | Oct 29, 2026 |
| INSM | Insmed Incorporated | $27.16B | Large cap | −7.54% | Oct 29, 2026 |
| ROIV | Roivant Sciences Ltd. | $26.55B | Large cap | +206.51% | Nov 9, 2026 |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | +100.35% | Nov 4, 2026 |
| BBIO | BridgeBio Pharma, Inc. | $15.52B | Large cap | +60.05% | Oct 28, 2026 |
| CORT | Corcept Therapeutics Incorporated | $12.95B | Large cap | +71.81% | Nov 4, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% | Oct 26, 2026 |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.52B | Large cap | +308.99% | Nov 24, 2026 |
| CYTK | Cytokinetics, Incorporated | $11.01B | Large cap | +109.36% | Nov 5, 2026 |
| IONS | Ionis Pharmaceuticals, Inc. | $10.56B | Large cap | +48.21% | Nov 4, 2026 |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +197.09% | Nov 3, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.